title: Head-to-head evaluation of five chlamydia tests relative to a quality-assured culture standard.
abstract: Nucleic acid amplification tests offer superior sensitivity for the detection of Chlamydia trachomatis infection, but many laboratories still use nonamplification methods because of the lower cost and ease of use. In spite of their availability for more than a decade, few studies have directly compared the nonamplification tests. Such comparisons are still needed in addition to studies that directly compare individual nonamplification and amplification tests. The purpose of this study was to evaluate and compare the performance characteristics relative to culture of five different tests for the detection of C. trachomatis with and without confirmation of positive results. The tests were applied to endocervical specimens from 4,980 women attending family planning clinics in the northwestern United States. The five nonculture tests included Chlamydiazyme (Abbott), MicroTrak direct fluorescent antibody (DFA) (Syva), MicroTrak enzyme immunoassay (EIA) (Syva), Pace 2 (Gen-Probe), and Pathfinder EIA (Sanofi/Kallestad). All positive results obtained with a nonculture test (except MicroTrak DFA) were confirmed by testing the original specimens with a blocking antibody test (Chlamydiazyme), a cytospin DFA (MicroTrak EIA and Pathfinder EIA), and a probe competition assay (Pace 2). The prevalence of culture-proven chlamydia was 3.9%. The sensitivities of the nonculture tests were in a range from 62 to 75%, and significant differences between tests in terms of sensitivity were observed. The positive predictive value for each test was 0.85 or higher. The specificities of the nonculture tests without performance of confirmations were greater than 99%. Performing confirmatory tests eliminated nearly all of the false positives.
authors.affiliation: Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
authors.forename: W J
authors.initials: WJ
authors.lastname: Newhall
authors.forename: R E
authors.initials: RE
authors.lastname: Johnson
authors.forename: S
authors.initials: S
authors.lastname: DeLisle
authors.forename: D
authors.initials: D
authors.lastname: Fine
authors.forename: A
authors.initials: A
authors.lastname: Hadgu
authors.forename: B
authors.initials: B
authors.lastname: Matsuda
authors.forename: D
authors.initials: D
authors.lastname: Osmond
authors.forename: J
authors.initials: J
authors.lastname: Campbell
authors.forename: W E
authors.initials: WE
authors.lastname: Stamm
mesh_terms: D002584:Cervix Uteri / Q000382:microbiology*; D002690:Chlamydia Infections / Q000175:diagnosis*; D002692:Chlamydia trachomatis / Q000302:isolation & purification*; D005189:False Positive Reactions; D005260:Female; D019085:Fluorescent Antibody Technique, Direct; D006801:Humans; D007124:Immunoenzyme Techniques; D007753:Laboratories / Q000592:standards; D015205:Northwestern United States; D011785:Quality Assurance, Health Care; D011786:Quality Control; D012680:Sensitivity and Specificity; D014626:Vaginal Smears